Jan 28, 2013 by Brian Orelli, PhDOncolytics Presents Promising Phase 1 Data in Colorectal CancerReolysin has already advanced into a phase 2 trial in colorectal cancer.
Jan 28, 2013 by Brian Orelli, PhDSanofi Moves Closer to Multiple Sclerosis Drug ApprovalIt would be Sanofi's second MS drug approval in as many years.
Jan 25, 2013 by Brian Orelli, PhDEarnings Season: It's All About ExpectationsBristol-Myers Squibb post horrible numbers but shares rise.
Jan 25, 2013 by Brian Orelli, PhDMerck Gains FDA Approval for First OTC Patch for Overactive BladderFor women only; men will still need a prescription for Oxytrol.
Jan 18, 2013 by Brian Orelli, PhDResearchers Select Eli Lilly's Drugs for Detection and Prevention of Alzheimer's DiseasePrevention trial will use Eli Lilly's solanezumab and Amyvid.
Jan 18, 2013 by Brian Orelli, PhDDeja Vu: A 10% Jump for That?Amarin jumps ahead of a potential NCE status update.
Jan 17, 2013 by Brian Orelli, PhDThe New Biotech Media BlitzDendreon and Spectrum Pharmaceuticals plan direct-to-consumer advertisements for their cancer treatments.
Jan 16, 2013 by Brian Orelli, PhDQuest Diagnostics Plans to Sell HemoCue Testing System DivisionMove in line with Quest's strategy to refocus on diagnostic informational services.
Jan 15, 2013 by Brian Orelli, PhDThe Trader's Guide to Flu Profits (or Lack Thereof)This is more short-term hype than long-term success.
Jan 15, 2013 by Brian Orelli, PhDFDA OKs Neuralstem Trial Treating Spinal Cord Injuries With Stem CellsNSI-566 has already shown promise in ALS and rat models of spinal cord injuries.
Jan 11, 2013 by Brian Orelli, PhDEli Lilly Investors' Big OpportunityPart of the bull case for the big pharma
Jan 11, 2013 by Brian Orelli, PhDCan J&J Get Its Diabetes Drug Past the Safety-First FDA?Another drug in the same class was rejected last year.
Jan 11, 2013 by Brian Orelli, PhDJ&J's Prostate Cancer Drug Zytiga Approved for Earlier Use in EUDecision follows a recommendation by the European Medicines Agency's Committee for Medical Products for Human Use in November.
Jan 11, 2013 by Brian Orelli, PhDThe Most Interesting Thing at JPMorgan's Health Care ConferenceA Twitter meme? Really!
Jan 11, 2013 by Brian Orelli, PhD3 Things I Wish I'd Heard at JPMorgan's Health Care ConferenceMissing sales numbers, waiting on the FDA, and a lack of big deals.
Jan 10, 2013 by Brian Orelli, PhDFDA Wakes Up to Insomnia Drug RiskLower doses recommended for drugs that contain zolpidem.
Jan 9, 2013 by Brian Orelli, PhDJ&J Diabetes Drug Faces Questions at FDA Advisory PanelThe FDA questioned the risk-benefit profile of canagliflozin.
Jan 8, 2013 by Brian Orelli, PhDWhere Will the Data Roller Coaster End?Peregrine says its mixed-up data is good enough to move onto phase 3.
